✨ Medicines Distribution Consents




15 APRIL NEW ZEALAND GAZETTE 1075

Note: This consent is valid for 2 years from the date of publication of this notice.

Dated this 7th day of April 1999.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2750

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Budesonide 1 mg/mL Spray, nasal suspension Douglas Pharmaceuticals Limited, Henderson, Auckland Amcal Budesonide Nasal Spray
Pholcodine 0.2% w/v Linctus Douglas Pharmaceuticals Limited, Mount Wellington, Auckland Amcal Cough Suppressant Double Strength
Pholcodine 0.1% w/v Linctus Douglas Pharmaceuticals Limited, Mount Wellington, Auckland Amcal Cough Suppressant Regular Strength
Choline theophyllinate 1.5% guaiphenesin 0.75% w/v Syrup Douglas Pharmaceuticals Limited, Mount Wellington, Auckland Amcal Expectorant Syrup
Paracetamol 24 mg/mL Suspension, oral Douglas Pharmaceuticals Limited, Mount Wellington, Auckland Amcal Paracetamol Pain & Fever Relief
Paracetamol 500 mg Tablet Douglas Pharmaceuticals Limited, Henderson, Auckland Amcal Paracetamol Pain Relief
Dolomite 400 mg Tablet, chewable Viminco A/S., Skaelskor, Denmark Frutin
Paracetamol 2.4% w/v Suspension, oral PSM Healthcare Limited, Wiri, Auckland Pharmacare Paramol Junior Suspension
Pholcodine 1 mg/mL Linctus PSM Healthcare Limited, Wiri, Auckland Pholcodine Linctus
Pholcodine 2 mg/mL Linctus PSM Healthcare Limited, Wiri, Auckland Pholcodine Strong Linctus

Dated this 7th day of April 1999.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2751

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Filgrastim 300 Β΅g/mL Injection, powder F Hoffmann-La Roche Limited, Basle, Switzerland; Parkedale Pharmaceuticals Inc., Rochester, Michigan, United States of America; and Amgen Inc., Juncos, Puerto Rico Neupogen
Filgrastim 600 Β΅g/mL Injection, pre-filled syringe F Hoffmann-La Roche Limited, Basle, Switzerland; and Parkedale Pharmaceuticals Inc., Rochester, Michigan, United States of America Neupogen

Dated this 7th day of April 1999.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2752



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1999, No 45


NZLII PDF NZ Gazette 1999, No 45





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
7 April 1999
Medicines Act 1981, New Medicine, Provisional Consent, Distribution
  • G. R. Boyd, Chief Advisor, Regulation and Safety

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
7 April 1999
Medicines Act 1981, Changed Medicine, Distribution, Filgrastim
  • G. R. Boyd, Chief Advisor, Regulation and Safety